Evidence map›Paper›PMID 25500839›Full record

ArticlePloS one2014

Role of IL-1β in experimental cystic fibrosis upon P. aeruginosa infection.

Jennifer Palomo, Tiffany Marchiol, Julie Piotet, Louis Fauconnier, Marieke Robinet, Flora Reverchon, Marc Le Bert, Dieudonnée Togbe, Ruvalic Buijs-Offerman, Marta Stolarczyk and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Playing With Fire: Proinflammatory Virulence Mechanisms of Group AFrontiers in cellular and infection microbiology · 2021
    Review
  8. Article
  9. Article
  10. Article
  11. IL-1β PromotesFrontiers in immunology · 2019
    Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Jennifer PalomoCNRS, UMR7355, Orleans, France; Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France.
Tiffany MarchiolArtimmune, Orléans, France.
Julie PiotetCNRS, UMR7355, Orleans, France; Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France.
Louis FauconnierArtimmune, Orléans, France.
Marieke RobinetArtimmune, Orléans, France.
Flora ReverchonCNRS, UMR7355, Orleans, France; Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France.
Marc Le BertCNRS, UMR7355, Orleans, France.
Dieudonnée TogbeArtimmune, Orléans, France.
Ruvalic Buijs-OffermanErasmus MC, Cell Biology department, Rotterdam, The Netherlands.
Marta StolarczykErasmus MC, Cell Biology department, Rotterdam, The Netherlands.
Valérie F J QuesniauxCNRS, UMR7355, Orleans, France; Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France.
Bob J ScholteErasmus MC, Cell Biology department, Rotterdam, The Netherlands.
Bernhard RyffelCNRS, UMR7355, Orleans, France; Experimental and Molecular Immunology and Neurogenetics, University of Orléans, Orléans, France; Institute of Infectious Disease and Molecular Medicine, IDM, Cape Town, South Africa.
Université d'Orléans · FRCentre National de la Recherche Scientifique · FRErasmus University Rotterdam · NLImmunologie et Neurogénétique Expérimentales et Moléculaires · FRWellcome Centre for Infectious Diseases Research in Africa · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cystic fibrosis is associated with increased inflammatory responses to pathogen challenge. Here we revisited the role of IL-1β in lung pathology using the experimental F508del-CFTR murine model on C57BL/6 genetic background (Cftr(tm1eur) or d/d), on double deficient for d/d and type 1 interleukin-1 receptor (d/d X IL-1R1-/-), and antibody neutralization. At steady state, young adult d/d mice did not show any signs of spontaneous lung inflammation. However, IL-1R1 deficiency conferred partial protection to repeated P. aeruginosa endotoxins/LPS lung instillation in d/d mice, as 50% of d/d mice succumbed to inflammation, whereas all d/d x IL-1R1-/- double mutants survived with lower initial weight loss and less pulmonary collagen and mucus production, suggesting that the absence of IL-1R1 signaling is protective in d/d mice in LPS-induced lung damage. Using P. aeruginosa acute lung infection we found heightened neutrophil recruitment in d/d mice with higher epithelial damage, increased bacterial load in BALF, and augmented IL-1β and TNF-α in parenchyma as compared to WT mice. Thus, F508del-CFTR mice show enhanced IL-1β signaling in response to P. aeruginosa. IL-1β antibody neutralization had no effect on lung homeostasis in either d/d or WT mice, however P. aeruginosa induced lung inflammation and bacterial load were diminished by IL-1β antibody neutralization. In conclusion, enhanced susceptibility to P. aeruginosa in d/d mice correlates with an excessive inflammation and with increased IL-1β production and reduced bacterial clearance. Further, we show that neutralization of IL-1β in d/d mice through the double mutation d/d x IL-1R1-/- and in WT via antibody neutralization attenuates inflammation. This supports the notion that intervention in the IL-1R1/IL-1β pathway may be detrimental in CF patients.

Indexed as

Pseudomonas aeruginosaAnimalsBronchoalveolar Lavage FluidCystic FibrosisCytokinesHistological TechniquesInterleukin-1betaLungMiceMice, Inbred CFTRMice, KnockoutNeutrophilsPseudomonas InfectionsReceptors, Interleukin-1 Type ISignal TransductionStatistics, NonparametricCytokinesIL1R1 protein, mouseInterleukin-1betaReceptors, Interleukin-1 Type ITumor Necrosis Factor-alpha

Identifiers

PMID25500839
PMCPMC4264861
OpenAlexW2168502452

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.